Related Experiment Video
Updated: Mar 24, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Optimizing adjunctive antithrombotic and anticoagulant therapy in primary PCI for STEMI
Pierre Deharo1, Hazim Rahbi, Thomas Cuisset
1Department of Cardiology, CHU Timone, Marseille, France - thomas.cuisset@ap-hm.fr.
Optimizing antithrombotic therapy for ST-elevation myocardial infarction (STEMI) is crucial. Balancing reduced thrombotic events with bleeding risk involves choosing appropriate anticoagulants and dual antiplatelet therapy, including newer P2Y12 inhibitors.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- ST-elevation myocardial infarction (STEMI) management presents challenges, particularly regarding antithrombotic strategies.
- Primary percutaneous coronary intervention (PPCI) is superior to fibrinolysis, but optimal antithrombotic use around PPCI is debated.
- Balancing antithrombotic efficacy with bleeding risk is paramount in STEMI patients.
Purpose of the Study:
- To review current antithrombotic strategies for STEMI patients undergoing PPCI.
- To discuss the optimal selection and timing of anticoagulants and antiplatelet agents.
- To highlight areas of ongoing debate and future research directions.
Main Methods:
- Review of current guidelines and recent clinical trial data on antithrombotic therapy in STEMI.
- Discussion of anticoagulant options: unfractionated heparin, low molecular weight heparin, and bivalirudin.
- Analysis of dual antiplatelet therapy (DAPT) regimens, including aspirin, P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor), and intravenous agents (cangrelor, GP2b3a inhibitors).
Main Results:
- Intravenous anticoagulants are recommended for all STEMI patients; LMWH may be preferred in PPCI. Bivalirudin is an option for high-bleeding-risk patients.
- DAPT with aspirin and a P2Y12 inhibitor is standard; newer agents like prasugrel and ticagrelor are preferred over clopidogrel.
- Timing of oral antiplatelet administration and use of intravenous agents remain areas of active discussion and limited consensus.
Conclusions:
- Optimal antithrombotic management in STEMI requires careful consideration of individual patient risk factors for thrombosis and bleeding.
- Current evidence supports specific anticoagulant and DAPT choices, with ongoing research into optimal timing and novel agents.
- Further research is needed to define the precise role of agents like cangrelor and refine strategies for high-risk STEMI populations.
More Related Videos
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Angina IV: Management